Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 1/2015

01-03-2015 | Original Article

Anti-Mullerian hormone normogram in an Irish subfertile population

Authors: M. N. Naasan, C. Harrity, L. Pentony, E. Mocanu

Published in: Irish Journal of Medical Science (1971 -) | Issue 1/2015

Login to get access

Abstract

Background

There has been much interest in the use of anti-Mullerian hormone (AMH) as a biomarker in the assessment of ovarian reserve, and debate on its use as a predictor of assisted reproductive technology (ART) outcomes. Normal levels have not been well defined, and age-based reference ranges may have a role in counselling patients.

Aims

To determine AMH levels in females attending with subfertility, identify age-specific centiles and the age-related decline, to create population normograms to be used in patient counselling prior to ART.

Methods

Retrospective study in a tertiary academic Assisted Conception Centre analysing AMH levels in female patients attending for investigation of subfertility between January 2009 and December 2011 (n = 3,058).

Results

Few patients have AMH levels within external laboratory pre-defined “normal fertility potential” ranges. Only 8.1 % had “optimal fertility” and 18.6 % “satisfactory”, with 54.6 % “low” fertility and 15.9 % in the “very low/undetectable” group. By age 32, over 50 % of women have AMH levels categorised as “low fertility” (AMH ≤19.5 pmol/L), increasing to 75 % by age 39. Based on a regression model a decrease in mean AMH of 1.72 pmol/L/year was measured.

Conclusions

We recommend that each ART centre defines their “own” normograms for accurate advice for and treatment of their patients. External laboratory-defined “normal” and “abnormal” AMH levels should be filtered and adapted to the reality of each population. These findings need to be considered when counselling patients and planning treatments as age-specific population normograms can provide a tailored approach.
Literature
1.
go back to reference Lane AH, Donahoe PK (1998) New insights into Müllerian inhibitory substance and its mechanism of action. J Endocrinol 158:1–6CrossRefPubMed Lane AH, Donahoe PK (1998) New insights into Müllerian inhibitory substance and its mechanism of action. J Endocrinol 158:1–6CrossRefPubMed
2.
go back to reference Themmen AP (2005) Anti-Mullerian hormone: its role in follicular growth initiation and survival and as an ovarian reserve marker. J Natl Cancer Inst Monogr 34:18–21CrossRefPubMed Themmen AP (2005) Anti-Mullerian hormone: its role in follicular growth initiation and survival and as an ovarian reserve marker. J Natl Cancer Inst Monogr 34:18–21CrossRefPubMed
3.
go back to reference Visser JA, Themmen AP (2005) Anti-Müllerian hormone and folliculogenesis. Mol Cell Endocrinol 234:81–86CrossRefPubMed Visser JA, Themmen AP (2005) Anti-Müllerian hormone and folliculogenesis. Mol Cell Endocrinol 234:81–86CrossRefPubMed
4.
go back to reference Durlinger ALL, Kramer P, Karels B et al (1999) Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology 140:5789–5796PubMed Durlinger ALL, Kramer P, Karels B et al (1999) Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology 140:5789–5796PubMed
5.
go back to reference Durlinger AL, Gruijters MJ, Kramer P et al (2001) Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 142:4891–4899PubMed Durlinger AL, Gruijters MJ, Kramer P et al (2001) Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 142:4891–4899PubMed
6.
go back to reference Kevenaar ME, Themmen AP, Laven JS et al (2007) Anti-Müllerian hormone and anti-Müllerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Hum Reprod 22:1547–1554CrossRefPubMed Kevenaar ME, Themmen AP, Laven JS et al (2007) Anti-Müllerian hormone and anti-Müllerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Hum Reprod 22:1547–1554CrossRefPubMed
7.
go back to reference Vigier B, Forest MG, Eychenne B et al (1989) Anti-Müllerian hormone produces endocrine sex reversal of fetal ovaries. Proc Natl Acad Sci USA 86(10):3684–3688CrossRefPubMedCentralPubMed Vigier B, Forest MG, Eychenne B et al (1989) Anti-Müllerian hormone produces endocrine sex reversal of fetal ovaries. Proc Natl Acad Sci USA 86(10):3684–3688CrossRefPubMedCentralPubMed
8.
go back to reference La Marca A, Giulini S, Tirelli A et al (2007) Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 22:766–771CrossRefPubMed La Marca A, Giulini S, Tirelli A et al (2007) Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 22:766–771CrossRefPubMed
9.
go back to reference Fanchin R, Schonäuer LM, Righini C et al (2003) Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 18:328–332CrossRefPubMed Fanchin R, Schonäuer LM, Righini C et al (2003) Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 18:328–332CrossRefPubMed
10.
go back to reference Van Rooij AJ, Broekmans FJM, Te Velde ER et al (2002) Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 17:3065–3071CrossRefPubMed Van Rooij AJ, Broekmans FJM, Te Velde ER et al (2002) Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 17:3065–3071CrossRefPubMed
11.
go back to reference Seifer DB, MacLaughlin DT, Christian BP et al (2002) Early follicular serum Müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 77:468–471CrossRefPubMed Seifer DB, MacLaughlin DT, Christian BP et al (2002) Early follicular serum Müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 77:468–471CrossRefPubMed
12.
go back to reference Nardo LG, Christodoulou D, Gould D et al (2007) Anti-Müllerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol 23:486–493CrossRefPubMed Nardo LG, Christodoulou D, Gould D et al (2007) Anti-Müllerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol 23:486–493CrossRefPubMed
13.
go back to reference De Vet A, Loven JS, de Jong FH et al (2002) Anti-Müllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77:357–362CrossRefPubMed De Vet A, Loven JS, de Jong FH et al (2002) Anti-Müllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77:357–362CrossRefPubMed
14.
go back to reference Cook CL, Siow Y, Taylor S et al (2000) Serum Müllerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril 73:859–861CrossRefPubMed Cook CL, Siow Y, Taylor S et al (2000) Serum Müllerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril 73:859–861CrossRefPubMed
15.
go back to reference La Marca A, Malmusi S, Giulini S et al (2004) Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 19:2738–2741CrossRefPubMed La Marca A, Malmusi S, Giulini S et al (2004) Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 19:2738–2741CrossRefPubMed
16.
go back to reference Nelson SM, Stewart F, Fleming R et al (2010) Longitudinal assessment of antiMüllerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril 93(4):1356–1358CrossRefPubMed Nelson SM, Stewart F, Fleming R et al (2010) Longitudinal assessment of antiMüllerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril 93(4):1356–1358CrossRefPubMed
17.
go back to reference Mohamed KA, Davies WA, Lashen H (2006) AntiMüllerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertil Steril 86:1515–1517CrossRefPubMed Mohamed KA, Davies WA, Lashen H (2006) AntiMüllerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertil Steril 86:1515–1517CrossRefPubMed
18.
go back to reference Streuli I, Fraisse T, Pillet C et al (2008) Serum anti Müllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 90:395–400CrossRefPubMed Streuli I, Fraisse T, Pillet C et al (2008) Serum anti Müllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 90:395–400CrossRefPubMed
19.
go back to reference Lutterodt M, Byskov AG, Skouby SO et al (2009) Anti-Müllerian hormone in pregnant women in relation to other hormones, fetal sex and in circulation of second trimester fetuses. Reprod Biomed Online 18:694–699CrossRefPubMed Lutterodt M, Byskov AG, Skouby SO et al (2009) Anti-Müllerian hormone in pregnant women in relation to other hormones, fetal sex and in circulation of second trimester fetuses. Reprod Biomed Online 18:694–699CrossRefPubMed
20.
go back to reference Barad DH, Weghofer A, Gleicher N (2009) Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. Fertil Steril 91:1553–1555CrossRefPubMed Barad DH, Weghofer A, Gleicher N (2009) Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. Fertil Steril 91:1553–1555CrossRefPubMed
21.
go back to reference Nardo LG, Gelbaya TA, Wilkinson H et al (2009) Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 92(1586–93):1553–1555 Nardo LG, Gelbaya TA, Wilkinson H et al (2009) Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 92(1586–93):1553–1555
22.
go back to reference Nelson SM, Yates RW, Fleming R et al (2007) Anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod 22:2414–2421CrossRefPubMed Nelson SM, Yates RW, Fleming R et al (2007) Anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod 22:2414–2421CrossRefPubMed
23.
go back to reference Eldar-Geva T, Ben-Chetrit A, Spitz IM et al (2005) Dynamic assays of inhibin B, anti-Müllerian hormone and oestradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod 20:3178–3183CrossRefPubMed Eldar-Geva T, Ben-Chetrit A, Spitz IM et al (2005) Dynamic assays of inhibin B, anti-Müllerian hormone and oestradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod 20:3178–3183CrossRefPubMed
24.
go back to reference Elgindy EA, El-Haieg DO, El-Sebaey A (2008) Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertil Steril 89:1670–1676CrossRefPubMed Elgindy EA, El-Haieg DO, El-Sebaey A (2008) Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertil Steril 89:1670–1676CrossRefPubMed
25.
go back to reference Al-Inany HG, Abou-Setta AM, Aboulghar M (2006) Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev (3):CD001750 Al-Inany HG, Abou-Setta AM, Aboulghar M (2006) Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev (3):CD001750
26.
go back to reference Doldi N, Persico P, Di Sebastiano F et al (2006) Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecol Endocrinol 22:235–238CrossRefPubMed Doldi N, Persico P, Di Sebastiano F et al (2006) Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecol Endocrinol 22:235–238CrossRefPubMed
27.
go back to reference Griesinger G, Diedrich K, Devroey P et al (2006) GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 12:159–168CrossRefPubMed Griesinger G, Diedrich K, Devroey P et al (2006) GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 12:159–168CrossRefPubMed
28.
go back to reference Laven JS, Mulders AG, Visser JA et al (2004) AntiMüllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 89:318–323CrossRefPubMed Laven JS, Mulders AG, Visser JA et al (2004) AntiMüllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 89:318–323CrossRefPubMed
29.
go back to reference Pigny P, Merlen E, Robert Y et al (2003) Elevated serum level of anti-Müllerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 88:5957–5962CrossRefPubMed Pigny P, Merlen E, Robert Y et al (2003) Elevated serum level of anti-Müllerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 88:5957–5962CrossRefPubMed
30.
go back to reference Park AS, Lawson MA, Chuan SS et al (2010) Serum anti-Müllerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J Clin Endocrin Metab 95:1786–1792CrossRef Park AS, Lawson MA, Chuan SS et al (2010) Serum anti-Müllerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J Clin Endocrin Metab 95:1786–1792CrossRef
31.
go back to reference Arabzadeh S, Hossein G, Rashidi BH et al (2010) Comparing serum basal and follicular fluid levels of anti-Müllerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome. Ann Saudi Med 30(6):442–447PubMedCentralPubMed Arabzadeh S, Hossein G, Rashidi BH et al (2010) Comparing serum basal and follicular fluid levels of anti-Müllerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome. Ann Saudi Med 30(6):442–447PubMedCentralPubMed
32.
go back to reference Wallace AM, Faye SA, Fleming R et al (2011) A multicentre evaluation of the new Beckman Coulter anti-Mullerian hormone immunoassay (AMH Gen II). Ann Clin Biochem 48:370–373CrossRefPubMed Wallace AM, Faye SA, Fleming R et al (2011) A multicentre evaluation of the new Beckman Coulter anti-Mullerian hormone immunoassay (AMH Gen II). Ann Clin Biochem 48:370–373CrossRefPubMed
33.
go back to reference Mulders AGMGJ, Laven JSE, Eijkemans MJC et al (2004) Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod 19:2036–2042CrossRefPubMed Mulders AGMGJ, Laven JSE, Eijkemans MJC et al (2004) Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod 19:2036–2042CrossRefPubMed
34.
go back to reference van Rooij IAJ, Broekmans FJM, Scheffer G et al (2005) Serum antiMüllerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 83:979–987CrossRefPubMed van Rooij IAJ, Broekmans FJM, Scheffer G et al (2005) Serum antiMüllerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 83:979–987CrossRefPubMed
35.
go back to reference Sowers MR, Eyvazzadeh AD, McConnell D et al (2008) AntiMüllerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 93:3478–3483CrossRefPubMedCentralPubMed Sowers MR, Eyvazzadeh AD, McConnell D et al (2008) AntiMüllerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 93:3478–3483CrossRefPubMedCentralPubMed
36.
go back to reference van Disseldorp J, Faddy MJ, Themmen AP et al (2008) Relationship of serum antiMüllerian hormone concentration to age at menopause. J Clin Endocrinol Metab 93:2129–2134CrossRefPubMed van Disseldorp J, Faddy MJ, Themmen AP et al (2008) Relationship of serum antiMüllerian hormone concentration to age at menopause. J Clin Endocrinol Metab 93:2129–2134CrossRefPubMed
37.
go back to reference Nelson SM, Messow MC, Wallace AM et al (2011) Normogram for the decline in serum anti Müllerian hormone: a population study of 9601 infertility patients. Fertil Steril 95:736–741CrossRefPubMed Nelson SM, Messow MC, Wallace AM et al (2011) Normogram for the decline in serum anti Müllerian hormone: a population study of 9601 infertility patients. Fertil Steril 95:736–741CrossRefPubMed
38.
go back to reference Seifer DB, Baker VL, Leader B (2011) Age specific anti-Müllerian hormone for 17,120 women presenting to fertility centres within the United States. Fertil Steril 95:747–750CrossRefPubMed Seifer DB, Baker VL, Leader B (2011) Age specific anti-Müllerian hormone for 17,120 women presenting to fertility centres within the United States. Fertil Steril 95:747–750CrossRefPubMed
39.
go back to reference Dewailly L, Gronier DH, Poncelet E et al (2011) Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 26:3123–3129CrossRefPubMed Dewailly L, Gronier DH, Poncelet E et al (2011) Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 26:3123–3129CrossRefPubMed
40.
go back to reference Li HWR, Ng EHY, Wong BPC et al (2012) Correlation between three assay systems for anti-Müllerian hormone (AMH) determination. J Assist Reprod Genet 29(12):1443–1446CrossRefPubMedCentralPubMed Li HWR, Ng EHY, Wong BPC et al (2012) Correlation between three assay systems for anti-Müllerian hormone (AMH) determination. J Assist Reprod Genet 29(12):1443–1446CrossRefPubMedCentralPubMed
41.
go back to reference Naasan M, Oluyede G, Kirkham C et al (2011) Is ovarian reserve in female cancer patients attending for cryopreservation different compared to age matched infertile patients. Hum Reprod 27(Suppl):248–261 Naasan M, Oluyede G, Kirkham C et al (2011) Is ovarian reserve in female cancer patients attending for cryopreservation different compared to age matched infertile patients. Hum Reprod 27(Suppl):248–261
42.
go back to reference Rustamov O, Smith A, Roberts SA et al (2012) Anti-Müllerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability. Hum Reprod 27(10):3085–3091CrossRefPubMed Rustamov O, Smith A, Roberts SA et al (2012) Anti-Müllerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability. Hum Reprod 27(10):3085–3091CrossRefPubMed
Metadata
Title
Anti-Mullerian hormone normogram in an Irish subfertile population
Authors
M. N. Naasan
C. Harrity
L. Pentony
E. Mocanu
Publication date
01-03-2015
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 1/2015
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-014-1089-0

Other articles of this Issue 1/2015

Irish Journal of Medical Science (1971 -) 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.